Experienced leader in HEOR field with deep understanding of local and national payer’s needs, with a track record of unique initiatives which lead to sustainable impact for the brand, the companies, the HCPs and ultimately to the patients. Helene is driven by improving health management of chronic conditions/ oncology and optimizing treatment pathway by deep understand of health data and their use with internal and external governance.
Dries Hens, M.D. is Chief Medical Officer and co-founder of LynxCare, a healthcare Big Data company on a mission to unlock clinical data. Dries is a medical doctor (KU Leuven, Belgium) with an MBA in Pharmaceutical Management (ESCP Europe, Paris). He is passionate about (new) business models where technology supports healthcare providers to deliver safer and more efficient healthcare, particularly in creating multistakeholder ecosystems fueled by outcome data.
Oisin Butler is the Integrated Evidence Generation Lead for Bayer Radiology. In this role, Oisin is responsible for evidence generation needs leveraging Real World Data (RWD) and Real World Evidence (RWE), serving all elements of the Bayer Radiology portfolio.
Oisin received his MSc from the Institute of Psychiatry, Kings College London and his PhD in Neuroscience from Humboldt University and the Max Planck Institute for Human Development in Berlin, where he focused on neuroimaging research.
Anila has over two decades of experience driven value in business decisions through strategic thought leadership and meaningful evidence generation. Her professional career began with conducting real world evidence (RWE ) research in Greece followed by several roles leading European and global pharma or CRO teams and observational research programs. Currently holds the position of Executive of Real-World Evidence (RWE) at SyneosHealth, where she provides strategy and leadership across strategic programs of multiple pharma or biotech clients, developing innovative real-world data platforms for integrated evidence generation planning throughout asset development and commercialization.
Anila is a respected RWLP advocate and often engages in presentations at industry webinars and conferences.She holds a Bachelor in Optometry from Athens Institute of Technology, and MBA from University of Indianapolis and a PHD in strategic Marketing.
Meritxell Sabidó is Director at Global Epidemiology Department, Neurology and Immunology Group - Merck Healthcare KGaA (Germany). She has worked extensively with Real Word Data and led regulatory studies based on registries and other data sources for the last 10 years. Meritxell is an MD specialized in Preventive Medicine and Public Health and has a PhD in Epidemiology.
Remon Helmy is a Senior Manager, Health Economics and Outcomes Research at Alexion, AstraZeneca Rare Disease Business Unit. He is a registered pharmacist with a master’s degree in Health Economics from the University of Heidelberg, Germany and a PhD with a focus on Treatment Adherence from the University of Basel, Switzerland. He also holds a Master of Business Administration. He has over 14 years of experience across different settings of pharmacy practice, academia, consulting, and the pharmaceutical industry.
Dr Davy Yeung’s career to date encompasses academia and the NHS. He has made valuable contributions to clinical research at the University of Cambridge, Imperial College, and other major academic institutions.
Dr Yeung was also the Head of Research at various UK Hospital Trusts. During his time in the NHS, he gained considerable insight into the governance and delivery of clinical research in the UK. This unique perspective enables our sponsors to select, initiate and manage UK investigative sites for their clinical studies rapidly and effectively. Having collaborated with a wide range of influential leaders in the field of clinical research, Dr Yeung is himself highly respected and well known in the UK’s healthcare research and development sector.
Experienced leader in HEOR field with deep understanding of local and national payer’s needs, with a track record of unique initiatives which lead to sustainable impact for the brand, the companies, the HCPs and ultimately to the patients. Helene is driven by improving health management of chronic conditions/ oncology and optimizing treatment pathway by deep understand of health data and their use with internal and external governance.
Shahbaz Pervaiz is RWE Services Director at LynxCare. He has close to a decade of experience in RWE studies (previously at IQVIA) and has a strong track-record supporting global pharma companies with their market access, pricing, product launch preparation and understanding of the patient journey.
.png)
Christian is a consultant pharmacist for medical information. He holds a Diploma in pharmaceutical technology from University of Leipzig and PhD in Medical Sciences of Charité University Medicine of Berlin. After several years working in public pharmacies, he joined Riemser Arzneimittel AG as Medical Advisor. He gained broad experiences in Medical Information, Medical Marketing, Clinical Operations and as Information officer. From 2012 to 2014 he has set up the German Operational Business Unit of LA-SER Analytica, a French CRO specialized in the management of pharmacoepidemiological studies. In 2014 he took over the responsibility of Non-Interventional Studies Team and in 2018 the responsibility of Data Generation Team of BAYER Vital GmbH in Leverkusen, Germany. In this position he drives digitalization and innovation in observational study conduct at BAYER. By leveraging innovative methodologies, his range of activity is from the development of data collection tools to measure adherence, explore eConsent, conduct investigator free fully digital studies or automatize data transfer from EHR2EDC.
Alexandre Templier has been working in the field of Life Sciences for more than 28 years. Passionate about Artificial Intelligence and data-driven decision-making in complex environments, Alexandre has dedicated his professional career to improving healthcare products and medical practice through Real World Data analytics and AI. Co-founder of Quinten Health and President of Quinten Health, he is particularly involved in the development of Quinten Health's activities within the healthcare sector (including projects for industry, healthcare providers, research institutions, and healthcare regulatory agencies). Alexandre was associate professor at Ecole Nationale Supérieure d'Arts & Métiers Paris Tech from 2001 to 2013.
Dr. Michael Happich is Senior Director - Value Evidence Outcomes Intl - at Eli Lilly based in Bad Homburg, Germany. He leads an international team of HTA & RWE scientists to support drug launches, HTA submissions and observational research for autoimmune diseases outside the US. Before joining the industry 18 years ago, he worked at the Helmholtz-Research Center in Munich. He is lecturer on pharmacoeconomics at the Goethe University Frankfurt, and Neubrandenburg University of applied sciences.
Veronika Schweighart is a serial entrepreneur with work experience in business development, strategic marketing and technology consulting. As Co-Founder and COO of Climedo, she oversees Key Account Management, Innovation and Partnerships, and is passionate about demonstrating the power of digital technologies to healthcare professionals.
